https://wiki.tradeville.ro/index.php?action=history&feed=atom&title=REPLIMUNE_GROUP_INCREPLIMUNE GROUP INC - Revizia istoricului2026-04-06T20:32:04ZIstoricul versiunilor pentru această pagină din wikiMediaWiki 1.39.2https://wiki.tradeville.ro/index.php?title=REPLIMUNE_GROUP_INC&diff=438171&oldid=prevAdmin: Pagină nouă: Pagina dedicata companiei REPLIMUNE GROUP INC listata cu simbolul US.REPL ==Descriere companie== Replimune Group, Inc. (https://www.replimune.com/) is a clinical-stage biotechnology company. The Company is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The Company applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The Company is focused on devel...2024-09-18T18:25:02Z<p>Pagină nouă: Pagina dedicata companiei REPLIMUNE GROUP INC listata cu simbolul US.REPL ==Descriere companie== Replimune Group, Inc. (https://www.replimune.com/) is a clinical-stage biotechnology company. The Company is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The Company applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The Company is focused on devel...</p>
<p><b>Pagină nouă</b></p><div>Pagina dedicata companiei REPLIMUNE GROUP INC listata cu simbolul US.REPL<br />
<br />
==Descriere companie==<br />
Replimune Group, Inc. (https://www.replimune.com/) is a clinical-stage biotechnology company. The Company is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The Company applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The Company is focused on developing a pipeline of oncolytic immunotherapy product candidates to provide clinical benefits to cancer patients. Its product candidates include RP1 (vusolimogene oderparepvec), RP2, and RP3. The Company is focused on Phase 2 clinical trials with its lead product candidate, RP1, in approximately 240 patients with a range of solid tumors.<br />
<br />
==Grafic actiuni companie==<br />
<iframe key="tradeville" path="graficSimbol/US.REPL" /><br />
<br />
==Ultimele stiri despre REPLIMUNE GROUP INC (US.REPL)==<br />
<dynamicpagelist><br />
category=US.REPL<br />
count=10<br />
order=descending<br />
addfirstcategorydate=false<br />
</dynamicpagelist><br />
<br />
[[Categorie:US.REPL]][[Categorie:Stiri despre companii]]</div>Admin